Dose range
6 → 36 mg/day
Route
Oral tablet, once daily, no food restriction
Indication(s)
Chronic weight management (April 1, 2026)

Titration schedule

StepDoseDurationNotes
16 mg/dayWeeks 1-4Starter
212 mg/dayWeeks 5-12
324 mg/dayWeeks 13-20
436 mg/dayWeek 21+Maximum

Important notes

  • This FDA-approved drug dosing chart is intended as a reference for clinicians and patients reviewing protocols, not a substitute for individualized prescriber guidance.
  • FDA-approved label dosing.
  • Compounded versions, where applicable, must be prepared by a licensed 503A or 503B compounding pharmacy. FDA has warned compounders that used salt forms (semaglutide sodium and semaglutide acetate), which are not the active ingredient in any approved drug.

References

  1. Foundayo (orforglipron) prescribing information / clinical literature.
  2. FDA, bulk drug substances used in compounding under section 503A (interim categories), accessed October 2026.
  3. USP <797>: Pharmaceutical Compounding — Sterile Preparations.